C ystic fibrosis (CF) lung disease is characterised by depletion of the airway surface liquid resulting in mucus retention, chronic bacterial airway infection and inflammation. Inflammation occurs very early and is more intense in CF than in non-CF patients with a similar bacterial load [1] . Neutrophils are recognised to play a central role by releasing proinflammatory mediators, such as reactive oxygen species and proteolytic enzymes. An imbalance has been proposed between pro-and antiinflammatory mediators, and some studies have suggested a deficiency in the anti-inflammatory response [2, 3] . Whether this is a primary event inherent to CF lung disease or is the consequence of neutrophilic inflammation has not been clarified.
In a recent study, lipoxin A 4 (LxA 4 ), a substance with anti-inflammatory properties, was described to be decreased in CF airways [4] . Lipoxins constitute the first recognised class of endogenous anti-inflammatory lipid-based autacoids that function as endogenous ''stop signals'' to downregulate or counteract the formation and actions of pro-inflammatory mediators [5] . Lipoxins (lipoxygenease interaction products) are endogenous anti-inflammatory mediators that also promote resolution of inflammation in vivo. Lipoxin generation has been demonstrated in a variety of human and experimental inflammatory, hypersensitivity and vascular diseases [6] . While the preliminary evidence suggests a relative deficiency of LxA 4 in CF airways, the group of CF patients included in that study [4] was small, and subgroup analysis was therefore not feasible to define whether lipoxin deficiency is a common feature in CF lung disease or whether it is present only in patients with intense neutrophilic inflammation.
Bronchial epithelial cells produce another compound with potential anti-inflammatory properties, the Clara cell protein 10 (CC-10) [7] . CC-10 is also known as uteroglobin or urine protein-1 and it is produced by nonciliated bronchial epithelium. Human CC-10 exhibits high homology with rabbit uteroglobin, which has multiple activities, including immunosuppressive, anti-inflammatory, antiproteinase, and antiphospholipase A 2 activities, suggesting that CC-10 might play a role in anti-inflammatory responses [7, 8] . CC-10-deficient mice demonstrate more severe inflammation than wild-type controls [9] . Lastly, CC-10 appears as one of the most abundant respiratory tract-derived proteins, making up ,7% of the total protein content of lung lavages from healthy nonsmokers [10] . CC-10 has been proposed to function as an anti-inflammatory agent, based on its ability to inhibit the activation of phospholipase A2 (PLA2), a key enzyme involved in the production of prostaglandins and other eicosanoids, as well as possessing antifibrotic activity [11, 12] . As yet, no information is available about CC-10 concentrations in airways of patients with CF.
In the present study, concentrations of both CC-10 and LxA 4 were assessed in a group of CF patients with a wide range of endobronchial inflammation as well as disease controls. It was hypothesised that there is no absolute, constitutive deficiency of LxA 4 and CC-10 in CF, but the lack of these substances may appear during pronounced chronic inflammation of the lungs. It was reasoned that if a defect in these anti-inflammatory mediators was specific for CF, it should be seen in CF patients with different degrees of airway inflammation and should not be seen in control subjects with airway inflammation unrelated to CF.
MATERIALS AND METHODS
Subjects, bronchoalveolar lavage and sample preparation To test the above-indicated hypothesis, all available bronchoalveolar lavage fluid (BALF) samples were used from the following two previous studies in CF patients. 1) The Bronchoalveolar lavage for the Evaluation of Antiinflammatory Treatment (BEAT) study, which had investigated inflammation in CF patients with normal lung function (forced expiratory volume in one second (FEV1) .80% predicted), and 2) the Glutathione (GSH) study, a study that included CF patients with FEV1 50-80% pred; these samples were included to obtain a broader range of disease activity [13, 14] . All these samples represented the whole CF group. Cellfree supernatant of BALF was analysed from 69 patients with CF. BALF from 14 subjects with chronic bronchitis was obtained during diagnostic work-up. Bronchoalveolar lavage (BAL) was performed in the lingula or middle lobe [15] . The return from the first fraction was retained separately from the other three fractions, which were pooled. Fractions 2-4 were filtrated via sterile 160-mm gauze, and protease inhibitors 0.5 mM EDTA, 500 mM Pefablock (Merck, Darmstadt, Germany), 5 mM E-64 and 50mM bestatin (both from Roche, Basel, Switzerland) were added to aliquots and centrifuged to remove cells. All manipulations were performed immediately on ice. Aliquots of the cell supernatant were stored at -80uC prior to analysis. Duration of storage ranged 3-5 yrs and was the same for the two study groups. To avoid problems associated with a potential instability of LxA 4 from repetitive freeze-thaw cycles, aliquots of the lavages were used that had not been previously thawed.
CF was diagnosed by means of a positive (chloride .60 mM) sweat test in each case. Additionally, the most frequent 30 mutations were searched for. Chronic bronchitis was defined by the presence of long-term (.3-month duration) respiratory tract symptoms, such as intermittent rhonchi, coarse crackles, and continuous dry or productive cough [16, 17] . These findings were not associated with bronchiectasis on computed tomography scans. None of the children had gross structural airway abnormalities or primary ciliary dyskinesia (excluded by bronchoscopy and nasal or bronchial biopsy (beat frequency and pattern, electron microscopy of cilia)), CF (excluded by negative sweat testing (chloride concentration ,40 mM)), passive or active smoke exposure (by history), immune deficiency (normal immunoglobulins, complement system, granulocyte function, T-and B-cell numbers and functions), or gastro-oesophageal reflux disease (two-point pH probe testing, BAL lipid-laden macrophages, upper gastrointestinal tract series). Asthma was not the principal diagnosis because neither history of atopy, wheezing or eosinophils were a finding in these children. The clinical characteristics of the patients' groups are given in the tables 1 and 2.
The study protocols were approved by the institutional review boards. Approval for the usage of the samples was given by the Ethics Committee of the University of Munich (Munich, Germany). Written informed consent was obtained from adult subjects, parents of the children and those children old enough before the original BEAT and GSH studies. 
Biochemical analysis

Statistical analysis
Two groups were compared by Mann-Whitney U-test and three groups by Kruskal-Wallis test with Dunn's post hoc test. Data are given as median values together with their range. Correlation analysis was performed by Spearman rank sum test and by calculation of linear regression lines. These analyses were primarily carried out in the whole group of CF patients. A p-value ,0.05 was considered significant. The CF group as a whole was much larger and skewed towards older subjects, compared with the group of children with chronic bronchitis. Therefore, to perform comparisons, the age of the two groups was adjusted by a systematic procedure. From the CF group, the oldest patients were removed stepwise in order to avoid a selection bias (one step51 yr), until the two groups had a comparable age that did not differ significantly. Thus, an upper cut-off value for age of 16 yrs was obtained and consistently used for all comparisons of the two groups.
This subgroup of CF patients did not differ in age and sex from the comparison group of subjects with chronic bronchitis. These age-adjusted CF patients were also subdivided into two groups according to their percentage of neutrophils in BAL (elevated (.10%) versus normal (,10 %)).
RESULTS
Lipoxin
The concentration of LxA 4 in BALF of the age-adjusted group of patients with CF did not differ from its concentration in the group of children with chronic bronchitis (fig. 1a) . The ageadjusted CF group was divided into patients with pronounced and mild inflammation in the lungs (relative polymorphonuclear granulocytes (PMN) count in BALF .10% and ,10% accordingly). No significant differences among these groups in LxA 4 BALF content were found ( fig. 1b) fig. 2 ).
Clara cell protein
The content of CC-10 in BALF of the CF patients studied was significantly lower than in the comparable control group (fig. 3a) . The lowest CC-10 values were observed in the CF patients with a relative PMN count in BALF of .10% ( fig. 3b ).
In addition, the CC-10/PMN ratio was significantly lower in this group of patients ( fig. 3c ). In the whole group of CF patients, the content of CC-10 in BALF correlated negatively with total cell count (r5 -0.34, p50.024), absolute (r5 -0.5, p50.001) and relative (r5 -0.38, p50.013) PMN counts ( fig. 4) . Only a marginal correlation between FEV1 and CC-10 was found in the whole group of CF patients (r50.33, p50.033; fig. 4b ). Analysis of Western blots revealed no proteolytic fragments of CC-10.
DISCUSSION
In the present study, the BALF content of CC-10 and LxA 4 , two molecules with hypothesised anti-inflammatory properties in patients with chronic lung diseases, was investigated. No evidence for a primary deficiency of these two mediators in CF lung disease was found, but evidence for a relative deficiency of CC-10 and LxA 4 in CF patients with pronounced bronchial inflammation, as well as weak correlations between the content of CC-10 and LxA 4 , the granulocyte (PMN) count in BALF and the lung function of the subjects.
Lipoxin A 4 The present study revealed no absolute deficiency of LxA 4 in CF patients. It was notable that the group of CF patients with pronounced inflammation, i.e. .10% PMN in BALF, had PMN numbers that were ,70 times higher than the CF group with a low PMN count; the concentrations of LxA 4 in BALF were the same. However, a relative deficiency in LxA 4 , expressed as the forced expiratory volume in one second; % pred: % predicted.
ANTI-INFLAMMATORY FACTORS IN CF V. STAROSTA ET AL.
LxA 4 /PMN ratio, was observed in CF patients with an elevated BALF PMN count. Together with a positive correlation between the number of PMNs and LxA 4 concentration in BALF in the CF patients, it can be concluded that a relative lack of LxA 4 may only be present in CF patients with marked inflammation. Unfortunately, the present authors were unable to find non-CF control subjects with the same degree of endobronchial inflammation as CF patients, and thus the present data do not allow a decision as to whether this phenomenon is specific for CF patients or is characteristic for any neutrophilic inflammation. Nevertheless, the data would not support the concept that lipoxin deficiency is a primary event in CF lung disease.
The in vitro and in vivo activities of LxA 4 include: 1) inhibition of neutrophil chemotaxis, adherence and transmigration; suppression of neutrophil activation (including activation of the transcription factor nuclear factor-kB, superoxide generation and elastase secretion); 2) suppression of interleukin-8 production by epithelia and leukocytes; 3) upregulation of monocyte chemotaxis; 4) upregulation of monocyte ingestion of apoptotic neutrophils; 5) prevention of neutrophil-mediated damage; and 6) promotion of the resolution of neutrophilmediated inflammation [5] . Many of these factors, which can be influenced by LxA 4, play a crucial role in the pathogenesis of lung damage in CF lung disease. The present data support the hypothesis that there is no primary deficiency of LxA 4 in CF, but deficiency can exist with respect to the relative production of LxA 4 in CF patients with pronounced inflammation.
Clara cell protein CF patients had lower levels of CC-10 than the patients with chronic bronchitis. At the same time, the most pronounced changes were found in CF patients with marked bronchial inflammation and levels of PMN .10% in BALF, whereas CF patients with mild inflammation had the same content of CC-10 as patients with chronic bronchitis. Taken together with the fact that there was a clear negative correlation between CC-10 content and the level of PMNs in the BALF, the conclusion may be drawn that a reduction of CC-10 in CF is a secondary phenomenon more likely to be associated with altered CC-10 production or secretion, damage to Clara cells or increased consumption of this protein. It is known that different environmental pollutants, including tobacco smoke, can lead to a decrease of the CC-10 content in BALF and serum CC-10 increases in acute or chronic lung disorders characterised by an increased airways permeability [18] [19] [20] . Decreased CC-10 concentrations in BALF are well described in acute lung injury [21] . The inflammatory response to lipopolysaccharide in the lung was associated with a marked reduction of CC-10 concentrations in BALF and lung homogenate, as well as of similar experiments, the lowest BALF CC-10 levels were detected in acute respiratory distress syndrome (ARDS) patients who eventually died [23] . In line with these results, a high concentration of CC-10, which also functions as a natural inhibitor of neutrophil function, decreased neutrophilmediated lung damage in patients with ARDS [24] . Decreased serum and BAL levels of CC-10 were also associated with bronchiolitis obliterans syndrome and airway neutrophilia in lung transplant recipients [25] . Therefore, the observed decrease in BALF CC-10 is unlikely to be a primary event, but rather the consequence of intense neutrophilic inflammation.
CC-10 has been proposed to function as an anti-inflammatory agent, based on its ability to inhibit the activation of PLA2, a key enzyme involved in the production of prostaglandins and other eicosanoids [11] , and to inhibit thrombin-induced platelet aggregation and chemotaxis [26] , as well as possessing antifibrotic activity [12, 27] . The inflammatory, fibrotic and oncogenic phenotypes of a CC-10 knockout mouse illustrate the significance of preventing the initiation of these processes in vivo. In CC-10-deficient mice, the threshold for the initiation of these processes was significantly lowered, resulting in the exacerbation of inflammation in response to pulmonary insults [28, 29] . The findings among CC-10-deficient mice demonstrate that the CC-10 -/-genotype results in more complex changes to airways than CC-10 deficiency per se [30] . Lung inflammation was significantly increased in CC-10 -/-mice compared with wild-type mice after infection. Importantly, restoration of CC-10 in the airways of CC-10 -/-mice abrogated increased viral persistence, lung inflammation and airway reactivity. These findings suggest a role for CC-10 and Clara cells in regulation of lung inflammatory and immune responses to infection [31] .
Not much is known about the function of Clara cell protein in the lungs of patients with chronic lung diseases. The present findings of Clara cell protein deficiency in cystic fibrosis patients, accompanied by a corresponding decrease in pulmonary function, suggest impaired anti-inflammatory capacity of airway mucosa in these patients, which may be of importance for the development of chronic airway infection and inflammation. Strategies to increase natural antiinflammatory agents, and thus influence the disruption of the balance between natural inflammatory and anti-inflammatory or protective factors, could be useful to modulate tissue destruction and the course of chronic lung disease in cystic fibrosis.
